Immix Biopharma, Inc. IMMX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s retained earnings?
- Immix Biopharma, Inc. (IMMX) reported retained earnings of -$114.55M in Q1 2026.
- How has Immix Biopharma, Inc.'s retained earnings changed year-over-year?
- Immix Biopharma, Inc.'s retained earnings decreased by 44.0% year-over-year, from -$79.57M to -$114.55M.
- What is the long-term trend for Immix Biopharma, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s retained earnings has grown at a 81.0% compound annual growth rate (CAGR), from -$5.37M to -$104.46M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.